Evidence map›Paper›PMID 33565033›Full record

ArticleCardiovascular toxicology2021

Rosuvastatin Reduces L-Type Ca

Nihal Ozturk, Serkan Uslu, Tanju Mercan, Orhan Erkan, Semir Ozdemir

Abstract read
PubMed Publisher
In one paragraph

Article in Cardiovascular toxicology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Statins and Cardiomyocyte Metabolism, Friend or Foe?Journal of cardiovascular development and disease · 2023
    Review
  5. Ellagic Acid Prevents CaCardiovascular toxicology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Nihal OzturkDepartment of Biophysics, Faculty of Medicine, Akdeniz University, Antalya, Turkey.ORCID 0000-0002-8681-1415
Serkan UsluDepartment of Biophysics, Faculty of Medicine, Akdeniz University, Antalya, Turkey.ORCID 0000-0002-0875-5905
Tanju MercanDepartment of Biophysics, Faculty of Medicine, Akdeniz University, Antalya, Turkey.ORCID 0000-0002-6711-6003
Orhan ErkanDepartment of Biophysics, Faculty of Medicine, Akdeniz University, Antalya, Turkey.ORCID 0000-0001-7226-2438
Semir OzdemirDepartment of Biophysics, Faculty of Medicine, Akdeniz University, Antalya, Turkey. osemir@akdeniz.edu.tr.ORCID 0000-0002-4807-7344
Akdeniz University · TR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rosuvastatin is one of the most used statins to lower plasma cholesterol levels. Although previous studies have reported remarkable cardiovascular effects of rosuvastatin (RSV), the mechanisms of these effects are largely unknown. In this study, we investigated the acute effects of RSV on L-type Ca

Indexed as

Calcium SignalingAdenylyl CyclasesAdrenergic beta-AgonistsAnimalsCalcium Channels, L-TypeCyclic AMPCyclic AMP-Dependent Protein KinasesIsoproterenolMaleMembrane PotentialsMyocardial ContractionMyocytes, CardiacRatsRats, WistarReceptors, Adrenergic, betaRosuvastatin CalciumAdenylyl CyclasesAdrenergic beta-AgonistsCalcium Channels, L-TypeCyclic AMPCyclic AMP-Dependent Protein KinasesIsoproterenolReceptors, Adrenergic, betaRosuvastatin CalciumCalcium currentCardiac myocytesContractilityRosuvastatinβ-adrenergic signaling

Identifiers

PMID33565033
OpenAlexW3128296437

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.